Head and neck cancer
Therapeutic area
Oncology
Rare disease
No
- Definition
- A primary or metastatic malignant neoplasm affecting the head and neck. Representative examples include oral cavity squamous cell carcinoma, laryngeal squamous cell carcinoma, and salivary gland carcinoma.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Head and neck cancer
- Therapeutic area
- Oncology
- head and neck cancer
- head and neck neoplasm
- head and neck tumors
- head and neck tumours
- head/neck neoplasm
- tumour of head and neck
- cancer of craniocervical region
- cancer of head and neck
- cancer of the head and neck
- craniocervical region cancer
- head and neck cancer
- head and neck malignant neoplasia
- malignant craniocervical region neoplasm
- malignant head and neck neoplasm
- malignant head and neck tumor
- malignant head and neck tumour
- malignant neoplasm of craniocervical region
- malignant neoplasm of head and neck
- malignant neoplasm of the head and neck
- malignant tumor of head and neck
- malignant tumor of the head and neck
- malignant tumour of head and neck
- malignant tumour of the head and neck
- All therapeutic areas
- Oncology
- Severity
- Severe
- MONDO ID
- MONDO:0005627
- Parent condition
- MONDO:0004992
Related records
Broader conditions (8)
- Cancer
- Cancer or benign tumor
- Disease
- Disease by etiologic mechanism
- Head and neck neoplasm
- Human disease
- Neoplasm
- Neoplastic disease or syndrome
Narrower conditions (261)
- ACTH-producing pituitary gland carcinoma
- Adenoid cystic carcinoma of oropharynx
- Ameloblastic carcinoma
- Angiosarcoma of the scalp
- Aniridia 2
- Aniridia 3
- Aryepiglottic fold cancer
- Bilateral retinoblastoma
- Carcinoma arising in nasal papillomatosis
- Carcinoma in situ of epiglottis
- Carcinoma in situ of hypopharynx
- Carcinoma in situ of nasopharynx
- Carcinoma in situ of oropharynx
- Carcinoma of floor of mouth
- Carcinoma of hard palate
- Carcinoma of lip
- Carcinoma of parotid gland
- Carcinoma of soft palate
- Ceruminous carcinoma
- Cheek mucosa cancer
Trials (1,815)
- "QUAD SHOT" Radiotherapy With Pembrolizumab in Patients With Recurrent Head & Neck Cancer
- [18F]HX4 PET/CT Imaging for Detection of Hypoxia
- [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
- [Ga-68]MTP220 PET for Biodistribution and Efficacy in Pancreatic Cancer and Head and Neck Cancers
- 177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors
- 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
- 2 Phase Use Of Educational Materials In Head And Neck Cancer Center
- 3'-Deoxy-3'-[18F] Fluorothymidine and Fludeoxyglucose F 18 PET Scans in Evaluating Response to Cetuximab, Cisplatin, and Radiation Therapy in Patients With Advanced Cancer of the Oropharynx, Larynx, or Hypopharynx
- 3D Printed Oral Stents for Patients With Head and Neck Cancer Receiving Radiation Therapy
- 3D Specimen Maps for RT Planning
- 3D Ultrasound, Specimen Examination by Surgeon, and MRI in Surgical Margin Assessment
- 4-HPR and FTI in Head and Neck Squamous Cell Carcinoma (HNSCC)
- A 3D Analysis of Mandibular Plating Strategies in Oromandibular Reconstruction.
- A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
- A Bidirectional Study in Exploring the Dynamic Changes of Plasma and Urine Metabolites of Head and Neck Cancer
- A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors
- A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors
- A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Relapsed/Refractory Head and Neck Cancer
- A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors
- A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck Cancer
Approved drugs (4)
Drugs in development (208)
- ABT-510 Phase 1
- Acetylcysteine Phase 2
- Adenosine diphosphate Phase 1
- ADU-S100 Phase 2
- Afatinib Phase 3
- Aldesleukin Phase 3
- Alisertib Phase 1
- Aminolevulinic acid hydrochloride Phase 1
- Amoxicillin Phase 2
- Antineoplaston A10 Phase 2
- Armodafinil Phase 1
- Aspirin Phase 1
- Atezolizumab Phase 2
- Autogene cevumeran Phase 1
- Avelumab Phase 1
- Azacitidine Phase 1
- Bempegaldesleukin Phase 2
- Bevacizumab Phase 2
- Biropepimut-S Phase 2
- Bleomycin Phase 2
Other linked drugs (11)
- AMXT-1501
- Barium
- Cetuximab sarotalocan
- Citric acid
- Curcumin
- Methylphenidate
- Monalizumab
- Oportuzumab monatox
- Ribavirin
- Suratadenoturev
- Zenocutuzumab